Fig. 9: Ruxolitinib synergizes with LY3214996 (ERKi) and CC-90001 (JNKi). | npj Precision Oncology

Fig. 9: Ruxolitinib synergizes with LY3214996 (ERKi) and CC-90001 (JNKi).

From: Lestaurtinib’s antineoplastic activity converges on JAK/STAT signaling to inhibit treatment naïve and therapy resistant forms ovarian cancer

Fig. 9

Indicated cells were treated with LY3214996 (70 µM, threefold dilution) or CC-90001 (70 µM, threefold dilution), alone and in combination with ruxolitinib (25 µM, threefold dilution) for 5–7 days. Relative cell viability was measured with crystal violet staining. a, c Synergy plots depicting Loewe scores were generated using SynergyFinder3.0. b, d Combination index (CI) scores were calculated using the Chou-Talalay method and Compusyn software. CI-ED50 = combination index at 50% fraction effected, CI-ED95 = combination index at 95% fraction effected, where the fraction effected represents precent cell death. Antagonism = >1 (black), additive = 1 (gray), synergy = <1 (blue), and highly synergistic = <0.3 (red). Pink highlighting = synergism identified using clinically achievable concentrations of both drugs.

Back to article page